Krystal Biotech, Inc. KRYS Business Segments — Gross margin
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept krys:OperatingGrossMarginPercentage.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s business segments — gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s business segments — gross margin?
- Krystal Biotech, Inc. (KRYS) reported business segments — gross margin of 95% in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — gross margin changed year-over-year?
- Krystal Biotech, Inc.'s business segments — gross margin increased by 1.1% year-over-year, from 94% to 95%.
- What does business segments — gross margin mean?
- The profit remaining after subtracting the direct costs of producing goods or services from total revenue.
- How do you interpret business segments — gross margin?
- An increase indicates improved production efficiency or higher pricing power, while a decrease may signal rising input costs or pricing pressure.
- How does business segments — gross margin compare across companies?
- Biotech peers typically show high gross margins due to the nature of proprietary drug manufacturing, though this varies based on manufacturing scale and outsourcing.